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LETTER TO THE EDITOR
Pharmacokinetic and Clinical Considerations for Monitoring Asparaginase Activity
Levels During Pegaspargase Therapy
To the Editor: We read with interest the report by Bleyer et al.
providing recommendations for therapeutic drug monitoring of
asparaginase (ASNase) activity levels during treatment with
pegaspargase [1]. Adequate asparagine depletion has been
correlated with improved clinical outcomes and we applaud the
authors’ initiative in developing and sharing a protocol for
monitoring ASNase activity levels during pegaspargase thera-
py [2,3]. However, wewould like to comment on several parameters
outlined in the proposed recommendation.
The authors suggest a target ASNase activity level of0.05 IU/
ml 4–7 days following pegaspargase treatment. However, based on
in vivo pharmacokinetic/pharmacodynamic (PK/PD) models from
the AALL07P4 trial and an analysis by Douer et al., a target level of
>0.05 IU/ml is inadequate [4,5].With amean half-life of 5–7 days,
PK/PD data suggests that on days 4–7, ASNase activity levels are
typically between 0.6–1.2 IU/ml depending on the dose utilized and
whether the dose is given during induction or consolidation [4,5].
Levels are near the higher end of this range with larger doses (e.g.,
2500 IU/m2) and during consolidation courses. More importantly,
following pegaspargase treatment, asparagine repletion occurs
when ASNase activity levels drop below 0.2–0.4 IU/ml [4,5]. This
is in contrast to earlier data with native Escherichia coli ASNase in
which asparagine repletion occurred when ASNase activity
dropped below 0.1 IU/ml [6,7]. Using the proposed algorithm by
Bleyer et al., a level of 0.1 on days 4–7 would prompt no change in
therapy, yet at levels this low, asparagine is likely no longer
depleted. With pegaspargase, the majority of patients’ ASNase
activity levels do not drop below 0.2 IU/ml until day 21 [4,5]. A day
4–7 ASNase level which is already below 0.2 likely indicates the
formation of neutralizing antibodies and should prompt clinicians
to seriously consider switching to Erwinia asparaginase. Patients
who have adequate levels on day 4–7 but low day 14–21 trough
levels (<0.2) can be considered for a pegaspargase dose increase or
interval decrease.
The authors recommend testing ASNase activity for patients
with clinical hypersensitivity and in those with prior exposure to
ASNase, such as in the relapsed setting. However, there is little to
no correlation between the formation of anti-ASNase antibodies
and clinical hypersensitivity reactions [8]. Hypersensitivity does
not always lead to antibody production, and antibody production
can occur despite a lack of hypersensitivity. For example, in the
CCG-1961 trial, 29% of patients without clinical hypersensitivity
developed anti-ASNase antibodies and had a significantly higher
relapse rate [8,9]. Thus, it is difficult to discern based upon
clinical parameters which patients may benefit from monitoring
ASNase activity levels. Testing ASNase activity solely in patients
with clinical hypersensitivity or prior exposure may lead to
overlooking patients who are at an increased risk of therapeutic
failure associated with inadequate asparagine depletion. Due to
the relatively low cost of ASNase activity testing compared with
the cost of relapse, the clinical availability of the assay, and the
strong correlation between asparagine depletion and improved
survival, we believe ASNase activity levels should be monitored
in all patients undergoing pegaspargase therapy.
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